CPO-301

Product Description

A first-in-class antibody drug conjugate developed by CSPC, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic non-small cell lung cancer (NSCLC) patients with EGFR mutations who are relapsed/refractory to or ineligible for EGFR targeting therapy such as 3rd-generation EGFR inhibitors including Osimertinib. Preclinical studies showed that CPO301 dose dependently inhibited the growth of human tumors with various EGFR-activating mutations or high expression of wild type EGFR protein in immunodeficient mice. In particular, CPO301 showed potent anti-tumor efficacy in a human NSCLC PDX model harboring EGFR triple mutations (Exon19Del, T790M and C797S) that are resistant to the thirdgeneration EGFR-TKI Osimertinib. (Sourced from: https://doc.irasia.com/listco/hk/cspc/announcement/a230612.pdf)

Mechanisms of Action: EGFR Inhibitor

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Conjupro Biotherapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None